PDG14 COST-UTILITY OF DALBAVANCIN VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH ABSSSI IN ITALY

Autor:	Rotundo, M., Bini, C., Marcellusi, A., Mennini, F.S.
Zdroj:	In Value in Health November 2019 22 Supplement 3:S599-S599
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect